Time to Breast Cancer Relapse Predicted By Primary Tumour Characteristics, Not Lymph Node Involvement

Fitzpatrick, Danielle; Lai, Christine S.; Parkyn, Robert; Walters, Donald L.; Humeniuk, V.; Walsh, David

doi:10.1007/s00268-013-2397-7

Cited by 9 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found a clear dose-response pattern in all patients with higher HR with increasing tumour characteristics (T stage and N stage), and the results suggested a benefit from no adjuvant therapy for recurrence-free survival. These are in line with previous findings on known risk factors for CR (Augestad et al, 2015;Cronin-Fenton et al, 2018;Fitzpatrick et al, 2014;Lyth et al, 2013;Mari et al, 2018;Paik et al, 2016;Watanabe et al, 2018). However, we found the increased risk from these exposures to be present primarily within the first 3-4 years after complete cancer remission.…”

Section: Comparison With Relevant Literaturesupporting

confidence: 92%

“…lished risk factor for CR(Augestad et al, 2015;Lyth et al, 2013;Watanabe et al, 2018), except in bladder cancer(Mari et al, 2018), and our results support these previous findings. These are in line with previous findings on known risk factors for CR(Augestad et al, 2015;Cronin-Fenton et al, 2018;Fitzpatrick et al, 2014;Lyth et al, 2013;Mari et al, 2018;Paik et al, 2016; These are in line with previous findings on known risk factors for CR(Augestad et al, 2015;Cronin-Fenton et al, 2018;Fitzpatrick et al, 2014;Lyth et al, 2013;Mari et al, 2018;Paik et al, 2016; …”

supporting

confidence: 92%

See 1 more Smart Citation

Time from incident primary cancer until recurrence or second primary cancer: Risk factors and impact in general practice

et al. 2019

View full text Add to dashboard Cite

Objective Specialised follow‐up care after cancer treatment is changing towards increased involvement of general practice. To ensure timely detection of new cancer events, knowledge is warranted on the timing of cancer recurrence (CR) and second primary cancer (SPC), including risk factors for CR. Methods This population‐based register study included 67,092 patients diagnosed with malignant melanoma, bladder, lung, ovarian, endometrial, colorectal and breast cancer in Denmark in 2008–2016. The time from primary cancer to CR or SPC and risk factors for prolonged time to CR were analysed and stratified on sex and primary cancer type. Results Cancer recurrence proportions ranged from 6% to 35%. The risk of CR increased profoundly within the first 3 years and then levelled off, except for breast cancer. A total of 3%–6% of patients had SPC, with monotonously increasing cumulative incidence proportions. Besides primary tumour characteristics, lower educational level, living alone and comorbidity were associated with earlier CR. For example, in female malignant melanoma, HRs and 95% confidence intervals were 0.47 (0.37–0.61) for high educational level, 1.40 (1.16–1.68) for living alone and 2.38 (1.53–3.70) for high comorbidity. Conclusion The results may inform stratified risk assessment in decision of frequency, location and duration of post‐cancer follow‐up care.

show abstract

Section: Comparison With Relevant Literaturesupporting

confidence: 92%

supporting

confidence: 92%

Time from incident primary cancer until recurrence or second primary cancer: Risk factors and impact in general practice

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Tumor size and lymph node status are considered the 2 most important prognostic factors in breast cancer 15,22. However, only primary tumor size was significantly correlated with recurrence in our study.…”

Section: Discussioncontrasting

confidence: 55%

Age distribution and outcomes in patients undergoing breast cancer resection in Saudi Arabia

Alabdulkarim

Hassanain

Bokhari

et al. 2018

SMJ

View full text Add to dashboard Cite

ObjectivesIn response to rising incidence and mortality we aimed to investigate the demographic characteristics of patients with operative breast cancer in our region.MethodsWe performed a retrospective study of 224 patients who underwent surgery for breast cancer at King Saud University Medical City, Riyadh, Kingdom of Saudi Arabia between 2005 and 2012.ResultsWe identified a young population overall with a mean age of 48.8±12.2 years (range: 26-93 years). Survival rate were however similar across all age groups with a 10-year overall survival of 87%.ConclusionPatients in our study were generally younger than those with breast cancer in Western nations. However, unlike Western countries, young age was not associated with worse outcomes.

show abstract

“…While time to breast recurrence was not significantly different among the three groups of tumor pairs, it was substantially lower in the ERneg B group (TTR: 34 months vs 84 and 82 months in groups A and C, respectively). A shorter latency to recurrence for ERneg tumors has been demonstrated in a multivariate model in which the ERneg primary tumors were also of higher grade and larger size ( ≥ 20 mm), and interestingly, four of the five ERneg tumors in our study were ≥ 20 mm. However, the shorter latency to recurrence may also be related to whether the second tumor is a new primary or a true recurrence.…”

Section: Discussionmentioning

confidence: 99%

DNA methylation in breast cancers: Differences based on estrogen receptor status and recurrence

Williams

Jawale

Schneider

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

DNA methylation plays a role in the etiology of primary breast cancers. We analyzed paired primary and second breast tumors to elucidate the role of methylation in recurrence. Methylation profiles from paired primary and second breast tumors of 23 women were assessed using the HumanMethylation450 BeadChip. Twelve women had estrogen receptor positive (ERpos) primary and second tumors, five had estrogen receptor negative (ERneg) primary and second tumors, and six had an ERpos primary tumor but an ERneg second tumor. Stratifying tumors by occurrence revealed that the greater methylation previously associated with ERpos tumors, is more pronounced in primary tumors than in second tumors. Further, ERneg second tumors are more methylated than ERpos second tumors among women who had ERpos primary tumors. Pathway analyses using gene lists generated from comparisons of methylation in ERpos primary tumors from the paired sets with ERpos tumors from six women without recurrences, identified differences between groups based on the ER status of the second tumor. Hypermethylated genes of significantly enriched pathways were differentially associated with survival. DNA methylation profiles of ERpos primary breast tumors support the development and use of tumor methylation profiles for stratifying women with breast cancer both for prognosis and therapy.

show abstract

Time to Breast Cancer Relapse Predicted By Primary Tumour Characteristics, Not Lymph Node Involvement

Cited by 9 publications

References 25 publications

Time from incident primary cancer until recurrence or second primary cancer: Risk factors and impact in general practice

Time from incident primary cancer until recurrence or second primary cancer: Risk factors and impact in general practice

Age distribution and outcomes in patients undergoing breast cancer resection in Saudi Arabia

DNA methylation in breast cancers: Differences based on estrogen receptor status and recurrence

Contact Info

Product

Resources

About